Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors.
- Author:
Se Un JEONG
1
;
Anuja Kashikar KEKATPURE
;
Ja Min PARK
;
Minkyu HAN
;
Hee Sang HWANG
;
Hui Jeong JEONG
;
Heounjeong GO
;
Yong Mee CHO
Author Information
- Publication Type:Original Article
- Keywords: Prostatic neoplasms; Carcinoma, ductal; Immunohistochemistry; Prognosis
- MeSH: Adenocarcinoma*; Carcinoma, Ductal; Follow-Up Studies; Immunohistochemistry; Neoplasm Grading; Prognosis; Prostate*; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Ribosomal Proteins; Sirolimus; Tumor Burden
- From:Journal of Pathology and Translational Medicine 2017;51(5):471-481
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Ductal adenocarcinoma (DAC) of the prostate is an uncommon histologic subtype whose prognostic factors and immunoprofile have not been fully defined. METHODS: To define its prognostic factors and immunoprofile, the clinicopathological features, including biochemical recurrence (BCR), of 61 cases of DAC were analyzed. Immunohistochemistry was performed on tissue microarray constructs to assess the expression of prostate cancer-related and mammalian target of rapamycin (mTOR) signaling-related proteins. RESULTS: During the median follow-up period of 19.3 months, BCR occurred in 26 cases (42.6%). DAC demonstrated a wide expression range of prostate cancer-related proteins, including nine cases (14.8%) that were totally negative for pan-cytokeratin (PanCK) immunostaining. The mTOR signaling-related proteins also showed diverse expression. On univariate analysis, BCR was associated with high preoperative serum levels of prostate-specific antigen (PSA), large tumor volume, predominant ductal component, high Gleason score (GS), comedo-necrosis, high tumor stage (pT), lymphovascular invasion, and positive surgical margin. High expressions of phospho-mTOR (p-mTOR) as well as low expressions of PSA, phospho-S6 ribosomal protein (pS6) and PanCK were associated with BCR. On multivariable analysis, GS, pT, and immunohistochemical expressions of PanCK and p-mTOR remained independent prognostic factors for BCR. CONCLUSIONS: These results suggest GS, pT, and immunohistochemical expressions of PanCK and p-mTOR as independent prognostic factors for BCR in DAC. Since DAC showed diverse expression of prostate cancer–related proteins, this should be recognized in interpreting the immunoprofile of DAC. The diverse expression of mTOR-related proteins implicates their potential utility as predictive markers for mTOR targeted therapy.
